Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL, Zaman K, Hoque M, Estivariz CF, Burns CC, Konopka-Anstadt JL, Mainou BA, Kovacs SD, An Q, Lickness JS, Yunus M, Snider CJ, Zhang Y, Coffee E, Abid T, Wassilak SGF, Pallansch MA, Oberste MS, Vertefeuille JF, Anand A. Wilkinson AL, et al. Among authors: wassilak sgf. Lancet Infect Dis. 2023 Sep;23(9):1062-1071. doi: 10.1016/S1473-3099(23)00139-1. Epub 2023 May 10. Lancet Infect Dis. 2023. PMID: 37178706 Clinical Trial.
Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.
Kalkowska DA, Wiesen E, Wassilak SGF, Burns CC, Pallansch MA, Badizadegan K, Thompson KM. Kalkowska DA, et al. Among authors: wassilak sgf. Risk Anal. 2024 Feb;44(2):379-389. doi: 10.1111/risa.14159. Epub 2023 Jun 21. Risk Anal. 2024. PMID: 37344376 Free PMC article.
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider CJ, Zaman K, Wilkinson AL, Binte Aziz A, Yunus M, Haque W, Jones KAV, Wei L, Estivariz CF, Konopka-Anstadt JL, Mainou BA, Patel JC, Lickness JS, Pallansch MA, Wassilak SGF, Steven Oberste M, Anand A. Snider CJ, et al. Among authors: wassilak sgf. Vaccine. 2023 Sep 22;41(41):6083-6092. doi: 10.1016/j.vaccine.2023.08.055. Epub 2023 Aug 29. Vaccine. 2023. PMID: 37652822 Free PMC article. Clinical Trial.
Outbreak response strategies with type 2-containing oral poliovirus vaccines.
Kalkowska DA, Wassilak SGF, Pallansch MA, Burns CC, Wiesen E, Durry E, Badizadegan K, Thompson KM. Kalkowska DA, et al. Among authors: wassilak sgf. Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A142-A152. doi: 10.1016/j.vaccine.2022.10.060. Epub 2022 Nov 17. Vaccine. 2023. PMID: 36402659 Free PMC article.
69 results